[go: up one dir, main page]

MX2019003710A - Compuestos y metodos de p2x3 y/o p2x2/3. - Google Patents

Compuestos y metodos de p2x3 y/o p2x2/3.

Info

Publication number
MX2019003710A
MX2019003710A MX2019003710A MX2019003710A MX2019003710A MX 2019003710 A MX2019003710 A MX 2019003710A MX 2019003710 A MX2019003710 A MX 2019003710A MX 2019003710 A MX2019003710 A MX 2019003710A MX 2019003710 A MX2019003710 A MX 2019003710A
Authority
MX
Mexico
Prior art keywords
compounds
useful
methods
administering
patients
Prior art date
Application number
MX2019003710A
Other languages
English (en)
Inventor
Saha Ashis
K Thompson Scott
Priestley Tony
Kundu Mrinalkanti
Nath Suvadeep
Original Assignee
Asana Biosciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asana Biosciences Llc filed Critical Asana Biosciences Llc
Publication of MX2019003710A publication Critical patent/MX2019003710A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente divulgación proporciona compuestos novedosos y métodos para preparar y utilizar estos compuestos. En una modalidad, los compuestos tienen la estructura de la fórmula (I), en donde R1-R7 se definen en el presente documento. En una modalidad adicional, estos compuestos son útiles en un método para regular uno o ambos de los receptores P2X3 o P2X2/3. En otra modalidad, estos compuestos son útiles para tratar el dolor en pacientes mediante la administración de uno o más de los compuestos a un paciente. En otra modalidad, estos compuestos son útiles para tratar la disfunción respiratoria en pacientes mediante la administración de uno o más de los compuestos a un paciente. (ver Fórmula).
MX2019003710A 2016-09-30 2017-09-27 Compuestos y metodos de p2x3 y/o p2x2/3. MX2019003710A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662402280P 2016-09-30 2016-09-30
PCT/US2017/053660 WO2018064135A1 (en) 2016-09-30 2017-09-27 P2x3 and/or p2x2/3 compounds and methods

Publications (1)

Publication Number Publication Date
MX2019003710A true MX2019003710A (es) 2019-06-24

Family

ID=61757797

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019003710A MX2019003710A (es) 2016-09-30 2017-09-27 Compuestos y metodos de p2x3 y/o p2x2/3.
MX2022009736A MX2022009736A (es) 2016-09-30 2019-03-28 Compuestos y metodos de p2x3 y/o p2x2/3.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022009736A MX2022009736A (es) 2016-09-30 2019-03-28 Compuestos y metodos de p2x3 y/o p2x2/3.

Country Status (13)

Country Link
US (5) US10174039B2 (es)
EP (1) EP3528813B1 (es)
KR (1) KR20190053963A (es)
CN (2) CN109996546B (es)
AR (1) AR109776A1 (es)
AU (1) AU2017335674A1 (es)
BR (1) BR112019006216A2 (es)
CA (1) CA3037748A1 (es)
IL (1) IL265648B2 (es)
MX (2) MX2019003710A (es)
RU (1) RU2019112740A (es)
TW (1) TW201827432A (es)
WO (1) WO2018064135A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3037748A1 (en) * 2016-09-30 2018-04-05 Asana Biosciences, Llc P2x3 and/or p2x2/3 compounds and methods
US10111883B1 (en) * 2017-09-18 2018-10-30 Bellus Health Cough Inc. Selective P2X3 modulators
JP7578602B2 (ja) 2019-02-25 2024-11-06 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー３）、リミテッド Ｐ２ｘ３修飾薬での治療
US11787780B2 (en) * 2020-06-22 2023-10-17 Corcept Therapeutics Incorporated Quaternary indazole glucocorticoid receptor antagonists
MX2023005801A (es) 2020-11-27 2023-05-29 Chiesi Farm Spa Derivados de ftalazina como inhibidores de purinoceptor 3 de p2x (p2x3).
KR20230113536A (ko) * 2020-11-27 2023-07-31 키에시 파르마슈티시 엣스. 피. 에이. P2x3 억제제로서 (아자)퀴놀린 4-아민 유도체
MX2024007590A (es) 2021-12-21 2024-08-20 Corcept Therapeutics Inc Antagonistas piperazino indazólicos del receptor de glucocorticoides.
AU2022421212A1 (en) 2021-12-21 2024-07-04 Corcept Therapeutics Incorporated Bicyclic indazole glucocorticoid receptor antagonists
CN114685308A (zh) * 2022-05-10 2022-07-01 杭州微流汇科技有限公司 一种自催化氰源一锅法制备芳基伯酰胺的方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US5035891A (en) 1987-10-05 1991-07-30 Syntex (U.S.A.) Inc. Controlled release subcutaneous implant
US5575815A (en) 1988-08-24 1996-11-19 Endoluminal Therapeutics, Inc. Local polymeric gel therapy
US5633002A (en) 1988-10-04 1997-05-27 Boehringer Ingelheim Gmbh Implantable, biodegradable system for releasing active substance
US5411738A (en) 1989-03-17 1995-05-02 Hind Health Care, Inc. Method for treating nerve injury pain associated with shingles (herpes-zoster and post-herpetic neuralgia) by topical application of lidocaine
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
US5266325A (en) 1990-09-28 1993-11-30 Hydro Med Science Division Of National Patent Development Corp. Preparation of homogeneous hydrogel copolymers
AU651654B2 (en) 1992-01-14 1994-07-28 Endo Pharmaceuticals Solutions Inc. Manufacture of water-swellable hydrophilic articles and drug delivery devices
JP3471122B2 (ja) 1995-04-26 2003-11-25 アルケア株式会社 医療用粘着配合物
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
SE508357C2 (sv) 1996-01-02 1998-09-28 Kay Laserow Mätinstrument för mätning av smärta jämte ett förfarande för att med ett mätinstrument mäta smärta
SE9604751D0 (sv) 1996-12-20 1996-12-20 Astra Ab New therapy
US6039967A (en) 1997-04-03 2000-03-21 Point Biomedical Corporation Intravesical drug delivery system
US6623040B1 (en) 1997-09-03 2003-09-23 Recot, Inc. Method for determining forced choice consumer preferences by hedonic testing
US6464688B1 (en) 2000-02-15 2002-10-15 Microsolutions, Inc. Osmotic pump delivery system with flexible drug compartment
JP4659332B2 (ja) 2000-10-13 2011-03-30 アルザ・コーポレーシヨン 微小突起を用いて皮膚を穿孔するための装置および方法
US7537795B2 (en) 2000-10-26 2009-05-26 Alza Corporation Transdermal drug delivery devices having coated microprotrusions
US6766319B1 (en) 2000-10-31 2004-07-20 Robert J. Might Method and apparatus for gathering and evaluating information
DE10058662A1 (de) * 2000-11-25 2002-05-29 Merck Patent Gmbh Verwendung von Pyrazolo[4,3-d]pyrimidinen
DE10060388A1 (de) * 2000-12-05 2002-06-06 Merck Patent Gmbh Verwendung von Pyrazolo [4,3-d]pyrimidinen
CA2466148C (en) 2001-11-01 2013-01-08 Spectrum Pharmaceuticals, Inc. Medical compositions for intravesical treatment of bladder cancer
DE60237425D1 (de) 2002-03-28 2010-10-07 Univerzita Palackeho V Olomouc PyrazoloÄ4,3-dÜpyrimidine, Verfahren zu ihrer Herstellung und therapeutische Anwendung
DK2561860T3 (en) 2002-05-31 2018-04-30 Titan Pharmaceuticals Inc Implantable polymer device for prolonged release of buprenorphine
CA2437639C (en) 2003-08-11 2016-07-05 Valera Pharmaceuticals, Inc. Long term drug delivery devices with polyurethane based polymers and their manufacture
US7858110B2 (en) 2003-08-11 2010-12-28 Endo Pharmaceuticals Solutions, Inc. Long term drug delivery devices with polyurethane based polymers and their manufacture
GB0327323D0 (en) 2003-11-24 2003-12-31 Pfizer Ltd Novel pharmaceuticals
WO2006054299A2 (en) 2004-11-18 2006-05-26 Transpharma Medical Ltd. Combined micro-channel generation and iontophoresis for transdermal delivery of pharmaceutical agents
JP2008520749A (ja) * 2004-11-23 2008-06-19 レディ ユーエス セラピューティックス， インコーポレイテッド 新規二環式ヘテロ環化合物、その調製のためのプロセス、およびその新規二環式ヘテロ環化合物を含む組成物
US20070039624A1 (en) * 2005-08-18 2007-02-22 Roberts Richard H Patient compliance system and method to promote patient compliance
JP2007055940A (ja) * 2005-08-24 2007-03-08 Astellas Pharma Inc ピラゾロピリミジン誘導体
US20090182140A1 (en) * 2005-12-02 2009-07-16 Mitsubishi Tanabe Pharma Corporation Alicyclic Heterocyclic Compound
WO2007063935A1 (ja) * 2005-12-02 2007-06-07 Mitsubishi Tanabe Pharma Corporation 芳香族化合物
CN101528717B (zh) * 2006-11-09 2013-04-24 弗·哈夫曼-拉罗切有限公司 噻唑和*唑-取代的芳基酰胺类化合物
WO2010054296A2 (en) 2008-11-07 2010-05-14 Combinent Biomedical Systems, Inc. Devices and methods for treating and/or preventing diseases
US20110046600A1 (en) 2008-12-05 2011-02-24 Crank Justin M Devices, systems, and related methods for delivery of fluid to tissue
WO2010118367A2 (en) * 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Antiviral pyrimidines
US20110117055A1 (en) * 2009-11-19 2011-05-19 Macdonald James E Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
CN103492389B (zh) * 2011-04-21 2016-09-14 原真股份有限公司 用作激酶抑制剂的吡唑并[4,3-d]嘧啶
DK3381917T3 (da) * 2013-01-31 2021-10-18 Bellus Health Cough Inc Imidazopyridinforbindelser og anvendelser deraf
KR20220112867A (ko) 2013-12-16 2022-08-11 에이비에스 디벨롭먼트 원 인코포레이티드 P2x3 및/또는 p2x2/3 화합물 및 방법
CZ307147B6 (cs) * 2015-05-14 2018-02-07 Ústav experimentální botaniky AV ČR, v. v. i. 5-Substituované 7-[4-(2-pyridyl)fenylmethylamino]-3-isopropylpyrazolo[4,3-d]pyrimidiny, jejich použití jako léčiva, a farmaceutické přípravky
CA3037748A1 (en) * 2016-09-30 2018-04-05 Asana Biosciences, Llc P2x3 and/or p2x2/3 compounds and methods

Also Published As

Publication number Publication date
US20200190096A1 (en) 2020-06-18
EP3528813A4 (en) 2020-06-03
IL265648A (en) 2019-05-30
US10174039B2 (en) 2019-01-08
EP3528813A1 (en) 2019-08-28
TW201827432A (zh) 2018-08-01
EP3528813B1 (en) 2025-04-16
AU2017335674A1 (en) 2019-04-18
US20240391925A1 (en) 2024-11-28
KR20190053963A (ko) 2019-05-20
BR112019006216A2 (pt) 2019-06-25
IL265648B1 (en) 2025-03-01
AR109776A1 (es) 2019-01-23
US11339169B2 (en) 2022-05-24
CN116854693A (zh) 2023-10-10
MX2022009736A (es) 2022-09-05
WO2018064135A1 (en) 2018-04-05
US20190092778A1 (en) 2019-03-28
CN109996546A (zh) 2019-07-09
US20180093991A1 (en) 2018-04-05
IL265648B2 (en) 2025-07-01
US10611768B2 (en) 2020-04-07
US12077543B2 (en) 2024-09-03
CN109996546B (zh) 2023-06-27
US20220227774A1 (en) 2022-07-21
CA3037748A1 (en) 2018-04-05
RU2019112740A (ru) 2020-11-02

Similar Documents

Publication Publication Date Title
MX2019003710A (es) Compuestos y metodos de p2x3 y/o p2x2/3.
CY1125963T1 (el) Ρυθμιστες υποδοχεα ρ2χ3 και ρ2χ2/3 διαμινοπυριμιδινης για χρηση στη θεραπεια βηχα
PE20190338A1 (es) Metodos de tratamiento de trastornos del desarrollo con gaboxadol
CY1122648T1 (el) Διαδικασια για την παρασκευη συνθεσεων που περιεχουν υαλουρονικο οξυ και υδροχλωρικη μεπιβακαϊνη
CY1125247T1 (el) Μεθοδοι θεραπειας καταθλιψης χρησιμοποιωντας ανταγωνιστες υποδοχεα ορεξινης-2
CY1119707T1 (el) Ενωσεις διαρυλικου αμιδιου ως αναστολεις της κινασης
MX391850B (es) Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington
EA201690069A1 (ru) Применение высоких доз придопидина для лечения болезни хантингтона
EA201790693A1 (ru) Коррекция фигуры
CY1124734T1 (el) Μορφες δοσολογιας αυξητικης ορμονικης μακρας δρασης
EA201690044A1 (ru) Модуляторы ядерного транспорта и их применение
UY35273A (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn
EA201790599A1 (ru) Соединения и композиции в качестве ингибиторов киназ
BR112016013734A2 (pt) Composto, composição farmacêutica, kit, e uso de um composto
MX2017014584A (es) Inhibidores heterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer.
MX391156B (es) Forma polimorfica de sepiapterina.
CO2020005919A2 (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
CL2019000661A1 (es) Inhibidores de dopamina–b–hidroxilasa penetrantes de la barrera hematoencefálica.
MX381102B (es) Benralizumab para usarse en el tratamiento de asma incrementando el volumen espiratorio forzado.
MX389589B (es) Dexmedetomidina o medetomidina para uso en el tratamiento de la ansiedad por separacion en perros.
BR112017002449A2 (pt) tratamento de sintomas associados com terapia de privação androgênica
EA202090416A1 (ru) Способы лечения симптомов гастропареза с использованием велусетрага
RU2014104644A (ru) Способ повышения эффективности лечения коров, больных острым гнойно-катаральным эндометритом
RU2014142874A (ru) Способ лечения похмельного синдрома у лиц, не относящихся к больным алкоголизмом